HF
NTLA icon

HRT Financial’s Intellia Therapeutics NTLA Stock Holding History

HRT Financial’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,800
Closed -$292K – 4995
2026
Q1 		$292K Buy
+22,800
New +$290K ﹤0.01% 2898

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

HRT Financial's NTLA Position: Q2 2026 in Review

HRT Financial increased its Intellia Therapeutics (NTLA) stake by 148% in Q2 2026, buying an estimated $10.4M and bringing the position to 1,243,317 shares worth $21M. The position accounts for 0.04% of the portfolio, ranked #459.

HRT Financial first reported a position in NTLA in Q3 2021 and has held it in 7 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • HRT Financial held 1,243,317 shares of Intellia Therapeutics worth $21M as of Q2 2026.
  • HRT Financial bought 740,980 Intellia Therapeutics shares in Q2 2026, an estimated $10.4M.
  • Intellia Therapeutics made up 0.04% of HRT Financial's portfolio in Q2 2026, its #459 holding.
  • HRT Financial first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.